Skip to content
Screener

Johnson & Johnson JNJ Q3 2026 earnings

Reported October 13, 2026 · Before market open

Revenue$25.4BBeat by $16.3M
Adjusted EPS$2.59Beat by $0.07
Revenue estimate$25.4B
EPS estimate$2.52
“Johnson & Johnson's strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio. In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
Joaquin Duato

Next report

Oct 13, 2026 (Today)
Revenue estimate$25.4B
EPS estimate$2.52

Financials

Q3 2026

Income statement

See full
Revenue$25.4B+5.9%
Gross profit$17.3B+3.7%
Net income$210.0M-95.9%
EPS (diluted)$0.09-95.8%

Valuation & ratios

Valuation

as of 09/28/26
See full
Market cap$655.37B+46.8%
P/E40.7×+22.9×
P/S6.6×+1.8×

Profitability

See full
Gross margin67.6%-0.5pp
Net margin16.2%-11.1pp

Segments

By geography

See full
Europe$5.4B-0.6%
Asia-Pacific, Africa$3.7B+1.0%

FAQ

When did Johnson & Johnson report Q3 2026 earnings?
Johnson & Johnson (JNJ) reported Q3 2026 earnings on October 13, 2026 before market open.
What were Johnson & Johnson's Q3 2026 revenue and EPS?
Johnson & Johnson reported revenue of $25.4B and adjusted eps of $2.59 for Q3 2026.
Did Johnson & Johnson beat estimates in Q3 2026?
Revenue beat the consensus estimate of $25.4B by $16.3M. EPS beat the consensus estimate of $2.52 by $0.07.
How did Johnson & Johnson's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 5.9% from $24.0B a year earlier.
Where can I find Johnson & Johnson's Q3 2026 SEC filings?
You can read the 8-K earnings release (0000200406-26-000189) directly on SEC EDGAR. The filing index links above go to sec.gov.